At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 349 enrolled
Drug / intervention
IC51biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
In Brief
A Phase 3 clinical trial evaluating IC51 for Japanese Encephalitis. Completed, enrolled 349 participants.
Detailed Summary
The study investigates the long term persistence the Japanese encephalitis vaccine IC51 and the need of a booster dose
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJapanese Encephalitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2005
Primary CompletionSep 2007
First PostedJan 2008
Study CompletionApr 2009
TodayJul 2026
First PostedJan 16, 2008
Enrollment StartOct 1, 2005
Primary CompletionSep 1, 2007
Study CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.5 years ago
Interventions
IC51biological